Perspective Therapeutics

Perspective Therapeutics
Perspective Therapeutics
CATX
NYSE
15.80 USD
456.34%

About

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations..

Financials Amount (in millions)

Income statement
Balance sheet
Cash flow

Ratios

Price and Volume
Volume
Ten Day Average Volume 705.2K
Three Month Average Volume 18.5M
High Low
Fifty-Two Week High 19.05 USD
Fifty-Two Week Low 2.05 USD
Fifty-Two Week High Date 15 May 2024
Fifty-Two Week Low Date 15 Sep 2023
Price and Volume
Current Price 15.8 USD
Beta 1
Relative Price Change
Four Week Relative Price Change 21.69%
Thirteen Week Relative Price Change 6.97%
Twenty-Six Week Relative Price Change 51.45%
Fifty-Two Week Relative Price Change 211.33%
Year-to-Date Relative Price Change 231.90%
Price Change
One Day Price Change 1.41%
Thirteen Week Price Change 14.49%
Twenty-Six Week Price Change 66.53%
Five Day Price Change 0.70%
Fifty-Two Week Price Change 290.12%
Year-to-Date Price Change 293.03%
Month-to-Date Price Change 16.18%
Per Share Data
Book Value
Book Value Per Share (Last Fiscal Year) 2.66772 USD
Book Value Per Share (Most Recent Quarter) 5.05741 USD
Tangible Book Value Per Share (Last Fiscal Year) 0.02707 USD
Tangible Book Value Per Share (Most Recent Quarter) 3.95898 USD
EBITD
EBITD Per Share (Trailing Twelve Months) -1.03857 USD
Revenue
Revenue Per Share (Last Fiscal Year) 0.05358 USD
Revenue Per Share (Trailing Twelve Months) -0.04365 USD
Dividend
Dividend Per Share (Last Fiscal Year) -99999.99 USD
Dividend Per Share (Trailing Twelve Months) 0 USD
Dividend Per Share (5 Year) -99999.99 USD
Earnings Per Share
Excluding Extraordinary Items (Last Fiscal Year) -1.39944 USD
Excluding Extraordinary Items (Trailing Twelve Months) -1.39365 USD
Normalized (Last Fiscal Year) -1.39944 USD
Basic Excluding Extraordinary Items (Last Fiscal Year) -1.39944 USD
Basic Excluding Extraordinary Items (Trailing Twelve Months) -1.39365 USD
Including Extraordinary Items (Last Fiscal Year) -1.73769 USD
Including Extraordinary Items (Trailing Twelve Months) -1.74852 USD
Cash
Cash Per Share (Last Fiscal Year) 0.32781 USD
Cash Per Share (Most Recent Quarter) 4.34362 USD
Cash Flow Per Share (Last Fiscal Year) -1.37127 USD
Cash Flow Per Share (Trailing Twelve Months) -1.1178 USD
Free Cash Flow Per Share (Trailing Twelve Months) -0.57493 USD
Margins
Cash Flow Revenue
Cash Flow Revenue (5 Year) -100,000
Cash Flow Revenue (Trailing Twelve Months) -100,000
Pretax Margin
Pretax Margin (Trailing Twelve Months) -99,999.99%
Pretax Margin (Last Fiscal Year) -2,796.79%
Pretax Margin (5 Year) -99,999.99%
Gross Margin
Gross Margin (Last Fiscal Year) -99,999.99%
Gross Margin (Trailing Twelve Months) -99,999.99%
Gross Margin (5 Year) -99,999.99%
Operating Margin
Operating Margin (Last Fiscal Year) -2,855.02%
Operating Margin (Trailing Twelve Months) -99,999.99%
Operating Margin (5 Year) -99,999.99%
Net Profit Margin
Net Profit Margin (Last Fiscal Year) -2,611.93%
Net Profit Margin (Trailing Twelve Months) -99,999.99%
Net Profit Margin (5 Year) -99,999.99%
Growth
Book Value
Book Value Per Share (5 Year) -99,999.99%
Tangible Book Value (5 Year) -99,999.99%
Free Operating Cash Flow
Free Operating Cash Flow (5 Year) -99,999.99%
Revenue
Revenue Change MRQ vs 1 Year Ago -74.81%
Revenue Growth (3 Year) -99,999.99%
Revenue Change (Trailing Twelve Months) -124.22%
Revenue Per Share Growth -99,999.99%
Revenue Growth (5 Year) -99,999.99%
Capital Spending Debt
Capital Spending (5 Year) -99,999.99%
Total Debt (5 Year) -99,999.99%
Dividends
Dividend Growth (3 Year) -99,999.99%
Earnings Per Share
EPS Change MRQ vs 1 Year Ago 57.58%
EPS Change (Trailing Twelve Months) -50.02%
EPS Growth (3 Year) -99,999.99%
EPS Growth (5 Year) -99,999.99%
EBITDA
EBITDA (5 Year) -99,999.99%
EBITDA (5 Year Interim) -99,999.99%
Net Profit Margin
Net Profit Margin Growth (5 Year) -99,999.99%
Valuation
Total Price to Book
Price to Tangible Book (Last Fiscal Year) 1.4K
Price to Tangible Book (Most Recent Quarter) 4
Price to Free Cash Flow
Price to Free Cash Per Share (Last Fiscal Year) -100,000
Price to Free Cash Per Share (Trailing Twelve Months) -100,000
Net Debt
Net Debt (Most Recent Quarter) -291,164,000
Net Debt (Last Fiscal Year) -7,513,000
Price to Sales
Price to Sales (Last Fiscal Year) 743
Price to Sales (Trailing Twelve Months) -100,000
Price to Earnings
PE Excluding Extraordinary Items (Last Fiscal Year) -100,000
PE Normalized (Last Fiscal Year) -100,000
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items High (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items Low (Trailing Twelve Months) -100,000
PE Including Extraordinary Items (Trailing Twelve Months) -100,000
Dividends
Dividend Yield (5 Year) -99,999.99%
Dividend Yield -99,999.99%
Current Dividend Yield 0.00%
Price to Book
Price to Book (Last Fiscal Year) 6
Price to Book (Most Recent Quarter) 3
Financial Strength
Debt to Equity
Long Term Debt to Equity (Last Fiscal Year) 2
Long Term Debt to Equity (Most Recent Quarter) 0
Payout Ratio
Payout Ratio (Last Fiscal Year) -99,999.99%
Payout Ratio (Trailing Twelve Months) -99,999.99%
Quick Ratio
Quick Ratio (Last Fiscal Year) -100,000
Quick Ratio (Most Recent Quarter) -100,000
Enterprise Value
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) -100,000
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) -100,000
Current Ratio
Current Ratio (Last Fiscal Year) 1
Current Ratio (Most Recent Quarter) 28
Free Cash Flow
Free Cash Flow (Last Fiscal Year) -38,003,000
Free Cash Flow (Trailing Twelve Months) -24,575,000
Net Interest Coverage
Net Interest Coverage (Last Fiscal Year) -100,000
Net Interest Coverage (Trailing Twelve Months) -100,000
Total Debt to Equity
Total Debt to Equity (Last Fiscal Year) 2
Total Debt to Equity (Most Recent Quarter) 1
Management Effectiveness
Return on Assets
Return on Assets (Last Fiscal Year) -48.02%
Return on Assets (Trailing Twelve Months) -19.37%
Return on Assets (5 Year) -99,999.99%
Return on Equity
Return on Equity (Last Fiscal Year) -57.70%
Return on Equity (Trailing Twelve Months) -21.80%
Return on Equity (5 Year) -99,999.99%
Return on Investment
Return on Investment (Last Fiscal Year) -54.42%
Return on Investment (Trailing Twelve Months) -20.14%
Return on Investment (5 Year) -99,999.99%

Cookie Settings

We use cookies to deliver and improve our services, analyze site usage, and if you agree, to customize or personalize your experience and market our services to you. You can read our Cookie Policy here.